Evidence map›Paper›PMID 32539777›Full record

ArticleJournal of nanobiotechnology2020

Photo-responsive degradable hollow mesoporous organosilica nanoplatforms for drug delivery.

Jie Fan, Zhipeng Zhang, Yaru Wang, Shiting Lin, Shun Yang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 47 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jie FanSchool of Chemistry and Chemical Engineering, Jiangsu Normal University, Xuzhou, 221116, Jiangsu, China.
Zhipeng ZhangSchool of Chemistry and Chemical Engineering, Jiangsu Normal University, Xuzhou, 221116, Jiangsu, China.
Yaru WangSchool of Chemistry and Chemical Engineering, Jiangsu Normal University, Xuzhou, 221116, Jiangsu, China.
Shiting LinSchool of Chemistry and Chemical Engineering, Jiangsu Normal University, Xuzhou, 221116, Jiangsu, China.
Shun YangSchool of Chemistry and Chemical Engineering, Jiangsu Normal University, Xuzhou, 221116, Jiangsu, China. yangshun@jsnu.edu.cn.
Jiangsu Normal University · CN

Funding

National Natural Science Foundation of China 51802127Natural Science Foundation of Jiangsu Province BK20170239
6 · The paper itself

Abstract

backgroundStimulus-responsive degradable mesoporous organosilica nanoparticles (MONs) have shown great promise as drug carriers via enhancing the efficiency of drug delivery and accelerating the degradation of nanocarriers. However, it remains a great challenge to develop novel light-enabled spatial and temporal degradable MONs with both superior responsiveness for efficient anti-cancer drug delivery and safe exocytosis.

resultsWe report a novel photo-responsive degradable hollow mesoporous organosilica nanoplatform (HMONs@GOQD). The platform is based on organosilica nanoparticles (HMONs) containing singlet oxygen (

conclusionsWe carried out in vitro and in vivo experiments using DOX as a model drug; DOX-HMONs@GOQDs exhibited high biocompatibility, accelerated degradation, and superior therapeutic efficacy during light irradiation, indicating a promising platform for clinical cancer therapy.

Indexed as

Drug CarriersQuantum DotsAnimalsAntineoplastic AgentsCell Line, TumorCell SurvivalDoxorubicinGraphiteMaleMiceMice, NudeNeoplasms, ExperimentalOrganosilicon CompoundsPhotochemical ProcessesAntineoplastic AgentsDoxorubicinDrug Carriersgraphene oxideGraphiteOrganosilicon CompoundsDrug deliveryGraphene oxide quantum dotsHollow mesoporous materialsOrganosilicaPhoto-responsive degradation

Identifiers

PMID32539777
PMCPMC7296706
OpenAlexW3034290278

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.